Meeting in-person drives conversation around iPSCs
ISSCR2022 enabled scientists, vendors and investors to meet face-to-face for the first time in several years.
Axol Bio were there in force and our colleagues enjoyed the opportunity to meet with old and new customers to talk shop, catch up, and discuss how the field is evolving following the effects of the pandemic and the birth of recent innovations that are driving the field forward.
Scientists agree that more must be done to improve uptake of iPSCs
Axol CEO, Liam Taylor, spent some time speaking with Daylon James and Arun Sharma as part of a segment for their Stem Cell podcast where they surveyed conference attendees to ask them their thoughts on the important questions for the field: What research talks inspired them? How did they feel being face-to-face at the meeting again? How has the pandemic impacted their work? And, most importantly, what are the current challenges facing the stem cell research field?
You can listen to Liam’s and others’ answers to these questions in the podcast episode below.
The three biggest challenges facing the iPSC field
Interestingly, when answering the ‘challenges’ question, there was consensus among the attendees that the biggest challenges facing the field were:
- The need to improve public perception of stem cell research and cell therapy opportunities. How do we improve public trust in ‘the science’?
- The need to make stem cell research more reliable, scalable and affordable. We need to make iPSCs more accessible for researchers
- The need to bridge the gap between the bench and the clinic. This can be achieved through manufacturing reproducible cells at scale to enable better assays and lower costs to end-users.
Listen to the full recording of the Stem Cell Podcast
Hosts Daylon James and Arun Sharma reflect on the ISSCR2022 and speak with attendees to learn about their highlights from the conference
Axol is improving access to iPSC-derived cells from disease backgrounds
Whether in monoculture or in co-culture with other cells, the insights gained from using human iPSC-derived cells from healthy or disease lines can transform assays.
At Axol we have over 60 lines from healthy and diseased patients that we can use to make iPSC-derived motor neurons from, including lines from Alzheimers Disease, Huntington’s Disease and ALS patients. We also have a host of isogenic control lines that can serve as controls for your experiments. All genetic information and patient profiles are available. View our disease lines here.
We can make brain cells, immune cells and cardiomyocytes for you from all our genetic lines in 8-12 weeks, providing you order a minimum of 10 vials.
In addition, if you have an iPSC line you would like differentiated into iPSC-derived motor neurons, or other cells, we can help.